0000014272-18-000168.txt : 20180906 0000014272-18-000168.hdr.sgml : 20180906 20180906163233 ACCESSION NUMBER: 0000014272-18-000168 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180827 FILED AS OF DATE: 20180906 DATE AS OF CHANGE: 20180906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOERNER CHRISTOPHER S. CENTRAL INDEX KEY: 0001543747 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 181057904 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE S CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 3 1 wf-form3_153626593451059.xml FORM 3 X0206 3 2018-08-27 0 0000014272 BRISTOL MYERS SQUIBB CO BMY 0001543747 BOERNER CHRISTOPHER S. BRISTOL-MYERS SQUIBB COMPANY 430 E. 29TH STREET, 14 FLOOR NEW YORK NY 10016 0 1 0 0 EVP, Chief Commercial Officer Market Share Units 2019-03-10 Common Stock, $0.10 par value 1179.0 D Market Share Units 2020-03-10 Common Stock, $0.10 par value 3135.0 D Market Share Units 2021-03-10 Common Stock, $0.10 par value 5477.0 D Market Share Units 2022-03-10 Common Stock, $0.10 par value 7045.0 D Performance Shares 2019-03-10 Common Stock, $0.10 par value 9401.0 D Performance Shares 2020-03-10 Common Stock, $0.10 par value 10953.0 D Performance Shares 2021-03-10 Common Stock, $0.10 par value 10568.0 D Restricted Stock Units 2019-02-02 Common Stock, $0.10 par value 4465.0 D These market share units will vest on March 10, 2019. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. One-half of these market share units will vest on each of March 10, 2019 and March 10, 2020. One-third of these market share units will vest on each of March 10, 2019, March 10, 2020, and March 10, 2021. Twenty-five percent of these market share units will vest on each of the first, second, third, and fourth anniversaries of the grant date, starting on March 10, 2019. Each performance share converts into one share of common stock upon distribution in the first quarter of 2019, subject to a Total Shareholder Return modifier. Each performance share converts into one share of common stock upon distribution in the first quarter of 2020. Each performance share converts into one share of common stock upon distribution in the first quarter of 2021. These restricted stock units will vest on February 2, 2019. Each restricted stock unit converts into one share of common stock upon vesting. EXHIBIT LIST: EX-24 Exhibit 24 - Christopher Boerner Power of Attorney /s/Lisa A. Atkins, attorney-in-fact for Christopher Boerner 2018-09-06 EX-24 2 poa.htm EXHIBIT 24 - CHRISTOPHER BOERNER POWER OF ATTORNEY

POWER OF ATTORNEY

    I, Christopher Boerner, Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Company (the "Company"), a corporation duly organized and existing under the laws of the State of Delaware, in the United States of America, and having its principal place of business at 430 E. 29th Street, 14th Floor, New York, New York, do hereby constitute and appoint each of Sandra Leung, Katherine R. Kelly and Lisa A. Atkins, individually, as my lawful attorney-in-fact and in my name, place and stead to execute and deliver any and all documents relating to insider reporting requirements under Section 16 of the Securities Exchange Act of 1934 with respect to securities issued by the Company, including, without limitation, the execution and filing of a Form ID and all Forms 3, 4 and 5, and to take such other action, as such attorney considers necessary or appropriate, to effectuate such transactions.  This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4, and 5 with respect to securities issued by the Company, unless earlier revoked.

    IN WITNESS WHEREOF, I have executed this Power of Attorney on this 30th day of August, 2018.


/s/Christopher Boerner
Christopher Boerner